+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib



EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib



Lung Cancer 85(3): 435-441



Somatic mutations in the epidermal growth factor receptor (EGFR) are predictors of efficacy for treatment with the EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer (NSCLC). A CA repeat polymorphism in intron 1 of the EGFR gene influences the transcription of the EGFR gene. This study evaluates the association between the CA repeat polymorphism and outcome in NSCLC patients treated with erlotinib. Number of CA repeats in the EGFR gene was evaluated with PCR-fragment length analysis by capillary electrophoresis in 432 advanced NSCLC patients treated with erlotinib irrespective of EGFR mutation status. Patients were dichotomized into harboring short allele (CA≤16 in any allele) or long alleles (CA>16 in both alleles). Number of repeats was correlated with clinical characteristic and outcome. A subgroup analysis was performed based on the somatic EGFR mutation status. In EGFR mutation positive patients (N=62) we demonstrate a significantly higher median progression free survival (HR=0.39 (0.22-0.70); p=0.002) and overall survival (HR=0.43 (0.23-0.78); p=0.006) in patients also harboring a short CA repeat length vs. a long (median follow-up time of 52.2 months). The result remained highly significant in a multivariate Cox proportional hazards model. This correlation was not seen in EGFR mutation negative patients. Our study demonstrate that in EGFR mutation positive NSCLC patients treated with erlotinib a low number of CA repeats in intron 1 of the EGFR gene is a predictor for both longer progression free survival and overall survival.

(PDF emailed within 0-6 h: $19.90)

Accession: 052747909

Download citation: RISBibTeXText

PMID: 25017413

DOI: 10.1016/j.lungcan.2014.06.016


Related references

EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib. Clinical Lung Cancer 2019, 2019

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. Journal of Cellular and Molecular Medicine 18(8): 1519-1539, 2015

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. Bmc Cancer 18(1): 191, 2018

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clinical Cancer Research 20(7): 2001-2010, 2014

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR. Journal of Experimental and Clinical Cancer Research 31: 65, 2013

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?. Cancer ChemoTherapy and Pharmacology 73(5): 1063-1070, 2014

151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs. Journal of Thoracic Oncology 11(4 Suppl): S123-S124, 2016

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. Esmo Open 1(4): E000063, 2016

EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. Lung Cancer 120: 82-87, 2018

EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. Lung Cancer 120: 82-87, 2018

CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. European Journal of Cancer 47(13): 1962-1970, 2011

EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Medical Journal 53(6): 1128-1135, 2013

EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC. Journal of Oncology Pharmacy Practice 18(2): 245-249, 2013

Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis. Journal of Cancer Research and Therapeutics 11(2): 397-402, 2016

Clinical Outcomes and Secondary Epidermal Growth Factor Receptor (EGFR) T790M Mutation among First-line Gefitinib, Erlotinib and Afatinib-treated Non-small Cell Lung Cancer Patients with Activating EGFR Mutations. International Journal of Cancer 2018, 2018